Novo Nordisk GLP-1 agonist semaglutide (semaglutide) weight loss Phase III STEP project 4 trials are all successful!) Based on the STEP clinical project data, Novo Nordisk submitted a New Drug Application (NDA) for semaglutide 2.4 mg subcutaneous injection to the US FDA in December 2020
Step 2: Lower the frequency
Should We All Be Taking GLP1s
Moderator: - Lus Loureno, Professional secretary FIP, Portugal Panellists: - Philippe Bouchard, Dental Surgeon Universit Paris Cit Rothschild hospital, AP-HP France - Zehra Yonel, Clinical Lecturer and Honorary Specialist Registrar in Restorative Dentistry, School of Dentistry, University of Birmingham, United Kingdom - Asma Yahyouche, Assistant Professor in Clinical Pharmacy and Prescribing/ GP non-medical pharmacist prescriber University of Birmingham, United Kingdom Watch video Digital event video 8 March 2024, 14:00 - 15:30 CET Gender Equity in the Health Workforce: Accelerating progress More Gender inequities persist in the pharmaceutical and health workforce, hindering the professional growth and opportunities for women
